IMUGENE LIMITED — Capital/Financing Update 2021

Jul 27, 2021

==> picture [116 x 41] intentionally omitted <==

ASX Announcement

INVESTOR WEBINAR

---

SYDNEY, Australia, 28 July 2021: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce it will hold an investor webinar on Thursday 29 July 2021 at 10:30am AEST with Executive Chairman Paul Hopper and Managing Director/CEO Leslie Chong to discuss the outcome of the Company’s capital raising.

Please register for the webinar at the following link: https://us02web.zoom.us/webinar/register/WN_0BiVCi3KTYarTWVDuNllzQ

Investors are invited to send questions prior to the webinar to matt@nwrcommunications.com.au After registering, you will receive a confirmation email about joining the webinar. A recording will be available at the same link shortly after the conclusion of the session.

For more information please contact:

Leslie Chong Managing Director and Chief Executive Officer T: +61 458 040 433 Follow us on Twitter @TeamImugene Like us on Facebook @Imugene Connect with us on LinkedIn @Imugene Limited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumors. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immunooncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia

IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com